Gut Bifidobacteria Enrichment Following Oral Lactobacillus-supplementation is Associated with Clinical Improvements in Children with Cystic Fibrosis

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2022 Jul 28

PMID 35902830

Authors

Kathryn J Ray

Clark Santee

Kathryn McCauley

Ariane R Panzer

Susan V Lynch

Affiliations

Soon will be listed here.

Abstract

Background: Relationships between gut microbiomes and airway immunity have been established in murine and human studies of allergy and asthma. Early life Lactobacillus supplementation alters the composition and metabolic productivity of the gut microbiome. However, little is known of how Lactobacillus supplementation impacts the gut microbiota in children with cystic fibrosis (CF) and whether specific microbiota states that arise following gut microbiome manipulation relate to pulmonary outcomes.

Methods: Stool samples were collected from CF patients enrolled in a multi-center, double-blind, randomized placebo-controlled trial of daily Lactobacillus rhamnosus strain GG (LGG) probiotic supplementation over a 12-month period. Fecal 16S rRNA biomarker sequencing was used to profile fecal bacterial microbiota and analyses were performed in QiiME.

Results: Bifidobacteria-dominated fecal microbiota were more likely to arise in LGG-treated children with CF (P = 0.04). Children with Bifidobacteria-dominated gut microbiota had a reduced rate of pulmonary exacerbations (IRR = 0.55; 95% CI 0.25 to 0.82; P = 0.01), improved pulmonary function (+ 20.00% of predicted value FEV; 95% CI 8.05 to 31.92; P = 0.001), lower intestinal inflammation (Calprotectin; Coef = - 16.53 μg g feces; 95% CI - 26.80 to - 6.26; P = 0.002) and required fewer antibiotics (IRR = 0.43; 95% CI 0.22 to 0.69; P = 0.04) compared to children with Bacteroides-dominated microbiota who were less likely to have received LGG.

Conclusions: The majority of pediatric CF patients in this study possessed a Bacteroides- or Bifidobacteria-dominated gut microbiota. Bifidobacteria-dominated gut microbiota were more likely to be associated with LGG-supplementation and with better clinical outcomes.

Citing Articles

The Link Between Dysbiosis, Inflammation, Oxidative Stress, and Asthma-The Role of Probiotics, Prebiotics, and Antioxidants.

Kleniewska P, Pawliczak R Nutrients. 2025; 17(1.

PMID: 39796449 PMC: 11722634. DOI: 10.3390/nu17010016.

subsp. BG-L47 boosts growth and activity of DSM 17938 and its extracellular membrane vesicles.

Ermann Lundberg L, Pallabi Mishra P, Liu P, Mata Forsberg M, Sverremark-Ekstrom E, Grompone G Appl Environ Microbiol. 2024; 90(7):e0024724.

PMID: 38888338 PMC: 11267924. DOI: 10.1128/aem.00247-24.

The gut-airway microbiome axis in health and respiratory diseases.

Ozcam M, Lynch S Nat Rev Microbiol. 2024; 22(8):492-506.

PMID: 38778224 DOI: 10.1038/s41579-024-01048-8.

The Effect of on the Fecal Microbiota, Short Chain Fatty Acids, Odorous Substances, and Blood Biochemical Indices of Cats.

Han B, Liang S, Sun J, Tao H, Wang Z, Liu B Microorganisms. 2024; 12(1).

PMID: 38257918 PMC: 10820841. DOI: 10.3390/microorganisms12010091.

Positioning the preventive potential of microbiome treatments for cystic fibrosis in the context of current therapies.

Cauwenberghs E, De Boeck I, Spacova I, Van Tente I, Bastiaenssen J, Lammertyn E Cell Rep Med. 2024; 5(1):101371.

PMID: 38232705 PMC: 10829789. DOI: 10.1016/j.xcrm.2023.101371.

References

Nielsen S, Needham B, Leach S, Day A, Jaffe A, Thomas T . Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci Rep. 2016; 6:24857. PMC: 4855157. DOI: 10.1038/srep24857. View

De Lisle R, Borowitz D . The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013; 3(9):a009753. PMC: 3753720. DOI: 10.1101/cshperspect.a009753. View

Jafari S, Mehdizadeh-Hakkak A, Kianifar H, Hebrani P, Ahanchian H, Abbasnejad E . Effects of probiotics on quality of life in children with cystic fibrosis; a randomized controlled trial. Iran J Pediatr. 2014; 23(6):669-74. PMC: 4025125. View

Turnbaugh P, Hamady M, Yatsunenko T, Cantarel B, Duncan A, Ley R . A core gut microbiome in obese and lean twins. Nature. 2008; 457(7228):480-4. PMC: 2677729. DOI: 10.1038/nature07540. View

Del Campo R, Garriga M, Perez-Aragon A, Guallarte P, Lamas A, Maiz L . Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: a double blind prospective study. J Cyst Fibros. 2014; 13(6):716-22. DOI: 10.1016/j.jcf.2014.02.007. View

Fouhy F, Ronan N, OSullivan O, McCarthy Y, Walsh A, Murphy D . A pilot study demonstrating the altered gut microbiota functionality in stable adults with Cystic Fibrosis. Sci Rep. 2017; 7(1):6685. PMC: 5532234. DOI: 10.1038/s41598-017-06880-y. View

Di Caro S, Tao H, Grillo A, Elia C, Gasbarrini G, Sepulveda A . Effects of Lactobacillus GG on genes expression pattern in small bowel mucosa. Dig Liver Dis. 2005; 37(5):320-9. DOI: 10.1016/j.dld.2004.12.008. View

Bruzzese E, Raia V, Spagnuolo M, Volpicelli M, De Marco G, Maiuri L . Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr. 2007; 26(3):322-8. DOI: 10.1016/j.clnu.2007.01.004. View

Di Nardo G, Oliva S, Menichella A, Pistelli R, De Biase R, Patriarchi F . Lactobacillus reuteri ATCC55730 in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2013; 58(1):81-6. DOI: 10.1097/MPG.0000000000000187. View

10.

Infante Pina D, Redecillas Ferreiro S, Torrent Vernetta A, Segarra Canton O, Maldonado Smith M, Gartner Tizziano L . [Improvement of intestinal function in cystic fibrosis patients using probiotics]. An Pediatr (Barc). 2009; 69(6):501-5. DOI: 10.1016/s1695-4033(08)75231-7. View

11.

Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O . Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2010; 45(6):536-40. DOI: 10.1002/ppul.21138. View

12.

Zmora N, Zilberman-Schapira G, Suez J, Mor U, Dori-Bachash M, Bashiardes S . Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. 2018; 174(6):1388-1405.e21. DOI: 10.1016/j.cell.2018.08.041. View

13.

Fujimura K, Lynch S . Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015; 17(5):592-602. PMC: 4443817. DOI: 10.1016/j.chom.2015.04.007. View

14.

Robertson R, Manges A, Finlay B, Prendergast A . The Human Microbiome and Child Growth - First 1000 Days and Beyond. Trends Microbiol. 2018; 27(2):131-147. DOI: 10.1016/j.tim.2018.09.008. View

15.

Bruzzese E, Raia V, Ruberto E, Scotto R, Giannattasio A, Bruzzese D . Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. J Cyst Fibros. 2017; 17(3):375-382. DOI: 10.1016/j.jcf.2017.10.014. View

16.

McCauley K, Durack J, Valladares R, Fadrosh D, Lin D, Calatroni A . Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. J Allergy Clin Immunol. 2019; 144(5):1187-1197. PMC: 6842413. DOI: 10.1016/j.jaci.2019.05.035. View

17.

Durack J, Kimes N, Lin D, Rauch M, McKean M, McCauley K . Delayed gut microbiota development in high-risk for asthma infants is temporarily modifiable by Lactobacillus supplementation. Nat Commun. 2018; 9(1):707. PMC: 5816017. DOI: 10.1038/s41467-018-03157-4. View

18.

Suez J, Zmora N, Zilberman-Schapira G, Mor U, Dori-Bachash M, Bashiardes S . Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell. 2018; 174(6):1406-1423.e16. DOI: 10.1016/j.cell.2018.08.047. View

19.

Fonseca W, Lucey K, Jang S, Fujimura K, Rasky A, Ting H . Lactobacillus johnsonii supplementation attenuates respiratory viral infection via metabolic reprogramming and immune cell modulation. Mucosal Immunol. 2017; 10(6):1569-1580. PMC: 5599307. DOI: 10.1038/mi.2017.13. View

20.

Cope E, Goldberg A, Pletcher S, Lynch S . Compositionally and functionally distinct sinus microbiota in chronic rhinosinusitis patients have immunological and clinically divergent consequences. Microbiome. 2017; 5(1):53. PMC: 5427582. DOI: 10.1186/s40168-017-0266-6. View